LIMERICK, Ireland — February 25, 2026 — Leads & Copy —
Kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF) announced financial results for the fourth quarter and full year ended December 31, 2025, with fourth-quarter revenues increasing by 24% to $17.0 million and SaaS revenue growing 29% to $16.2 million.
The company reported achieving positive Adjusted EBITDA for the second consecutive year, with Annual Recurring Revenue (ARR) reaching $74.1 million at December 31, 2025. All dollar amounts are presented in Canadian dollars unless otherwise stated.
Total revenues for 2025 increased 29% to $63.3 million, compared to $48.9 million for 2024, and SaaS revenue grew 33% to $59.4 million for the year ended December 31, 2025, versus $44.6 million for 2024. Gross profit was $47.9 million, up 30% from $36.8 million for the full year of 2024. The gross margin for the full year ended December 31, 2025 was 76%, from 75% for all of 2024.
The net loss for 2025 was $2.3 million, compared with $7.7 million for the year ended December 31, 2024. Full year EBITDA was $14.7 million, compared with $5.6 million for the full year of 2024, and Adjusted EBITDA was $9.5 million, compared with $7.0 million for the full year of 2024. The Net Revenue Retention Rate (NRR), which reflects the expansion of ARR by customers on the platform at the start of 2025 over the course of the year, was 115% for the year ended December 31, 2025.
Total revenues increased 24% to $17.0 million in the fourth quarter of 2025, compared to $13.7 million for the fourth quarter of 2024. SaaS revenue for the fourth quarter of 2025 grew 29% to $16.2 million, versus $12.5 million for the fourth quarter of 2024. Fourth-quarter 2025 gross profit was $13.2 million, up 27% from $10.4 million in gross profit for the fourth quarter of 2024. Gross margin in the fourth quarter of 2025 was 78%, compared to 75% for the fourth quarter of 2024, and 76% for the third quarter of 2025.
The net loss for the fourth quarter of 2025 was $3.6 million, compared with a net loss of $2.5 million for the fourth quarter of 2024. EBITDA in the fourth quarter of 2025 was $1.3 million, compared with $1.1 million for the fourth quarter of 2024. Adjusted EBITDA in the fourth quarter of 2025 was $4.2 million, compared with $2.6 million for the fourth quarter of 2024. Total ARR was $74.1 million at December 31, 2025, an increase of 24% from $59.7 million at December 31, 2024.
Throughout 2025, Kneat solidified its position as the global standard for validation lifecycle management. The Company’s Kneat Gx platform was recognized by G2 as the #1 Pharma and Biotech Software for both the Fall and Winter 2025 reports, earning a near-perfect customer satisfaction score of 98/100.
In 2025, the company achieved a record year for new customer acquisitions, including nine major strategic wins with strong multi-year growth potential. Collectively, these new strategic customers represent more than 300,000 employees across the life sciences sector, spanning pharmaceuticals, medical devices, technology, and specialty chemicals.
Early in 2025, Kneat entered a partnership with Capgemini, bringing together systems integration expertise with the Kneat Gx platform. Recent platform enhancements include DataStream APIs, expanded eLogbook functionality, and a suite of AI features purpose-built for GxP-regulated environments, including a content review assistant, natural-language analysis expert, user-support expert, and real-time language translation.
The company strengthened its executive leadership with the appointment of Donal O’Sullivan as Chief Product Officer and the transition of co-founder Kevin Fitzgerald to Chief Innovation Officer.
Kneat enters 2026 with strong operational momentum. In January 2026, Kneat announced that a leading provider of technologies for biopharma research and manufacturing selected Kneat for equipment validation at several of its sites around the world. In February 2026, Kneat announced that a global maker of pharmaceutical packaging, dispensers and drug delivery systems selected Kneat for Commissioning, Qualification and Validation.
Also in February, Kneat was named the Gold winner in the Healthcare, Pharmaceuticals, and Related Industries category at the 2026 Stevie® Awards for Sales & Customer Service.
With a solid balance sheet and growing footprint in the pharmaceutical manufacturing supply chain, Kneat expects to outpace 2025’s incremental ARR. Kneat anticipates typical second-half seasonality, this growth combined with exceptional revenue retention, reinforces Kneat’s proven durable growth model.
Eddie Ryan, Chief Executive Officer of Kneat, and Dave O’Reilly Chief Financial Officer of Kneat, hosted a conference call to discuss Kneat’s fourth-quarter and full-year 2025 results and hold a Q&A session for analysts and investors via webcast on Thursday, February 26, 2026, at 9:00 a.m. ET.
Kneat Solutions provides companies in regulated industries with efficiency in validation and compliance through its digital validation platform Kneat Gx. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies have shown that Kneat Gx reduces man-hours associated with validation documentation by up to 50%, accelerates review and approval cycles by up to 50%, and consistently supports higher standards of regulatory compliance.
Source: Kneat
